BDX- Becton, Dickinson and Company
Healthcare · Medical Instruments & Supplies
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 12 analysts
12-Month Price Target
$195.67
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $182.91
Graham Number
√(22.5 × EPS × Book Value)
$107.97
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$48.52
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
6/10
60% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
6.6%Return on equity - measures how efficiently capital is used
Positive profit margin
4.2%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+5.4%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
-31.4%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
68.84×Low financial leverage reduces risk of distress
Current ratio above 1
0.86×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$382M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.36%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Nov 5, 2026
51
days
EPS (TTM)
$5.78
P/E (TTM)
31.6
Fwd P/E
13.8
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.36%
5Y Avg Annual
$3.0260
Last Payment
$1.0500
Ex-Date
09/09/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest09/09/2026 | 09/30/2026 | $1.0500 | 2.30% |
06/09/2026 | 06/30/2026 | $1.0500 | 2.30% |
03/10/2026 | 03/31/2026 | $1.0500 | 2.30% |
12/08/2025 | 12/29/2025 | $0.8255 | 1.81% |
09/08/2025 | 09/29/2025 | $0.8176 | 1.79% |
06/09/2025 | 06/30/2025 | $0.8176 | 1.79% |
03/10/2025 | 03/31/2025 | $0.8176 | 1.79% |
12/09/2024 | 12/30/2024 | $0.8176 | 1.79% |
Magic Number
Shares needed to self-fund your next purchase
$182.91
Price
$1.0500
Last div. (quarterly)
175
shares
Own 175 BDX shares ($32,009.25) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$32,009.25
New shares / year
+4 shares
Dividend Calculator
2.30% yieldEstimate BDX dividend income at the current rate.
Per year
$229.62
Per month
$19.14
≈ 54.7 shares at $4.2/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
BDX vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Location
Franklin Lakes, United States
Employees
72,000
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Becton, Dickinson and Company (BDX) stock trades at $182.91, up 2.85% on the day. With a market capitalization of $49.82 billion, BDX is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 31.6, a forward P/E of 13.8 and earnings per share (EPS) of $5.78. Over the most recent period the company reported 5% year-over-year revenue growth and a net profit margin of 4.2%. Below you'll find BDX's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
BDX - Frequently Asked Questions
Is Becton, Dickinson and Company (BDX) a good stock to buy in 2026?
Becton, Dickinson and Company (BDX) shows risks such as high leverage (debt/equity of 68.8). Whether BDX is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is BDX's stock price today?
Becton, Dickinson and Company (BDX) trades at $182.91, up 2.85% on the session. Prices on this page update throughout the trading day.
Does BDX pay a dividend?
Yes. Becton, Dickinson and Company pays an annual dividend of $4.20 per share, a dividend yield of 2.36%. The most recent ex-dividend date was September 9, 2026. Its payout ratio is about 72% of earnings.
Is BDX overvalued?
With a P/E ratio of 31.6×, BDX is valued above the broad-market average for the healthcare sector. Its PEG ratio is 1.11. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is BDX's market cap?
Becton, Dickinson and Company (BDX) has a market capitalization of $49.82 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.